Symbiotec Pharmalab IPO Lists Flat on NSE, Slips 0.99% on BSE
- September 1, 2026
- Posted by: Neeraj Pandey
- Category: IPO
Symbiotec Pharmalab lists at Rs 988 on NSE, flat versus issue price. BSE opens at Rs 978.20, down 0.99 percent. Issue price Rs 988. Subscribed 71.26 times overall. Market cap about Rs 6,285.53 Cr.
Quick Answer
The Symbiotec Pharmalab IPO listing today saw the stock debut at Rs 988 on the NSE, unchanged from its Rs 988 issue price, while BSE shares opened at Rs 978.20, a marginal 0.99 percent discount. The mainboard pharma and biotech IPO was subscribed 71.26 times overall. The listing came in well below what grey market indicators had suggested ahead of listing.
Symbiotec Pharmalab IPO Listing Today: The Symbiotec Pharmalab IPO was subscribed 71.26 times overall by the time bidding closed on 27 August 2026. Within that demand, qualified institutional buyers (QIBs) bid for 172.03 times their reserved portion, non institutional investors (NIIs) put in 73.63 times their quota, and retail investors subscribed 12.96 times the shares set aside for them. Before looking at how the stock performed on debut, here is a recap of the Symbiotec Pharmalab IPO itself, followed by the full Symbiotec Pharmalab IPO listing details.
Click Here – Get Free Investment Predictions
Symbiotec Pharmalab IPO
Symbiotec Pharmalab Limited raised its capital through a book building issue worth Rs 1,757 crore, made up of a fresh issue of shares worth Rs 150 crore and an offer for sale of Rs 1,607 crore by the promoter and existing investors. The issue listed on both the NSE and the BSE, with a tentative listing date of 1 September 2026. Bidding ran from 24 August 2026 to 27 August 2026, at a face value of Rs 2 per share and a price band of Rs 938 to Rs 988 per share. Anyone tracking the Symbiotec Pharmalab IPO listing today will find the full set of dates and terms in the table below.
| Particular | Detail |
|---|---|
| Allotment Date | 28 August 2026 |
| IPO Open Date | 24 August 2026 |
| IPO Close Date | 27 August 2026 |
| Refund Initiation | 31 August 2026 |
| Issue Size | Rs 1,757 crore (1,77,86,442 shares) |
| Face Value | Rs 2 per share |
| Lot Size | 15 shares |
| Issue Price | Rs 988 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE, BSE |
| Listing Date | 1 September 2026 |
Check Live Stock Data on the Univest Screener
Symbiotec Pharmalab Listing
On its listing day, Symbiotec Pharmalab shares opened at Rs 988 apiece on the NSE, exactly in line with the Rs 988 issue price. On the BSE, the stock opened lower at Rs 978.20, a 0.99 percent discount to the issue price. The company’s market capitalisation stood at about Rs 6,285.53 crore on listing, based on BSE data. The Symbiotec Pharmalab IPO listing fell well short of grey market expectations for a stronger debut, and instead turned out to be a largely muted affair for a mainboard pharma issue of this size. For investors who missed allotment, the Symbiotec Pharmalab IPO listing price now serves as the reference point for deciding whether to buy the stock on the exchanges.
About the Symbiotec Pharmalab IPO
Symbiotec Pharmalab Limited is an Indore based, research and development driven pharmaceutical and biotechnology company with capabilities across three platforms, organic chemistry, biotechnology, and complex injectables. With more than 30 years of experience, the firm has grown from a lab scale steroidal hormone API manufacturer into an industrial scale, backward integrated manufacturing platform, and it holds approvals from regulators such as the US FDA and the EU-GMP authority. Promoters of the company are Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP, while Rosewood Investments and India Business Excellence Fund III were among the selling shareholders in the offer for sale. JM Financial was the lead book running lead manager, alongside Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities, with MUFG Intime India as registrar. Investors who followed the Symbiotec Pharmalab IPO listing today can use this background to judge whether the muted debut reflects valuation concerns or broader market sentiment around recent mainboard offers. The details above round out the full picture of the Symbiotec Pharmalab IPO listing for readers who applied in the offer.
Download the Univest iOS App or Univest Android App to track Symbiotec Pharmalab live share price and get daily stock recommendations.
Symbiotec Pharmalab Limited Financials
A look at Symbiotec Pharmalab Limited’s recent financial performance helps put the Symbiotec Pharmalab IPO listing in context for anyone tracking the stock after its debut.
| Year Ended | 31 Mar 2026 (Rs cr.) | 31 Mar 2025 (Rs cr.) | 31 Mar 2024 (Rs cr.) |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Revenue | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| Net Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowings | 387.91 | 540.92 | 247.21 |
Explanation
Symbiotec Pharmalab Limited’s revenue rose about 15 percent, from Rs 755.98 crore in the year ended 31 March 2025 to Rs 872.26 crore in the year ended 31 March 2026. Profit after tax climbed roughly 14 percent over the same period, moving from Rs 96.79 crore to Rs 109.90 crore, while EBITDA improved from Rs 206.11 crore to Rs 231.97 crore, pointing to steady margin discipline alongside the topline growth. This steady financial trajectory is one of the factors investors are weighing after the Symbiotec Pharmalab IPO listing.
Grey market premium (GMP) is an unofficial, unregulated indicator for the Symbiotec Pharmalab IPO that is not endorsed by SEBI, NSE, or BSE. Investors looking for indicative GMP data around the Symbiotec Pharmalab IPO listing can go through other relevant sources, though such figures should never be the sole basis for an investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs
What was the Symbiotec Pharmalab IPO listing price?
Ans. Symbiotec Pharmalab shares listed at Rs 988 on the NSE, flat against the Rs 988 issue price, and opened at Rs 978.20 on the BSE, a 0.99 percent discount.
Was the Symbiotec Pharmalab IPO listing a premium or a discount?
Ans. The listing was largely flat. NSE shares opened unchanged from the issue price while BSE shares opened at a marginal 0.99 percent discount, well below what grey market indicators had suggested ahead of listing.
How much was the Symbiotec Pharmalab IPO subscribed?
Ans. The IPO was subscribed 71.26 times overall, with QIBs at 172.03 times, NIIs at 73.63 times, and retail investors at 12.96 times their respective quotas.
What is the issue price of the Symbiotec Pharmalab IPO?
Ans. The issue price was fixed at Rs 988 per share, at the upper end of the Rs 938 to Rs 988 price band.
What is the lot size of the Symbiotec Pharmalab IPO?
Ans. The lot size was 15 shares, translating to a minimum retail investment of about Rs 14,820 at the upper price band.
Who is the registrar for the Symbiotec Pharmalab IPO?
Ans. MUFG Intime India Private Limited is the registrar for the Symbiotec Pharmalab IPO.
What does Symbiotec Pharmalab do?
Ans. Symbiotec Pharmalab is a pharmaceutical and biotechnology company based in Indore that develops and manufactures active pharmaceutical ingredients, with a focus on corticosteroid and steroidal hormone APIs, across organic chemistry, biotechnology, and complex injectables platforms.
Where can I track the Symbiotec Pharmalab IPO listing performance?
Ans. Investors can track the Symbiotec Pharmalab IPO listing performance and live share price movement on the NSE and BSE, or through the Univest platform.
Did the Symbiotec Pharmalab IPO listing match grey market expectations?
Ans. No. The Symbiotec Pharmalab IPO listing came in well below what grey market indicators had suggested, with the stock instead debuting close to its issue price.
